Targeting Alzheimer's disease with gene and cell therapies. (19th June 2018)

• Record Type: Journal Article
• Authors: Loera‐Valencia, R.; Piras, A.; Ismail, M. A. M.; Manchanda, S.; Eyjolfsdottir, H.; Saido, T. C.; Johansson, J.; Eriksdotter, M.; Winblad, B.; Nilsson, P.
• Is Part Of: Journal of internal medicine. Volume 284:Number 1(2018)
• Page Start: 2
• Page End: 36
• Publication Date: 2018-06-19
• Subjects: Alzheimer's disease -- gene therapy -- cell therapy -- neprilysin -- tau -- induced neurogenesis; Internal medicine -- Periodicals; Medicine -- Periodicals; 616
• DOI: 10.1111/joim.12759
• Languages: English
• ISSNs: 0954-6820

Abstract

Abstract: Alzheimer's disease (AD) causes dementia in both young and old people affecting more than 40 million people worldwide. The two neuropathological hallmarks of the disease, amyloid beta (Aβ) plaques and neurofibrillary tangles consisting of protein tau are considered the major contributors to the disease. However, a more complete picture reveals significant neurodegeneration and decreased cell survival, neuroinflammation, changes in protein and energy homeostasis and alterations in lipid and cholesterol metabolism. In addition, gene and cell therapies for severe neurodegenerative disorders have recently improved technically in terms of safety and efficiency and have translated to the clinic showing encouraging results. Here, we review broadly current data within the field for potential targets that could modify AD through gene and cell therapy strategies. We envision that not only Aβ will be targeted in a disease‐modifying treatment strategy but rather that a combination of treatments, possibly at different intervention times may prove beneficial in curing this devastating disease. These include decreased tau pathology, neuronal growth factors to support neurons and modulation of neuroinflammation for an appropriate immune response. Furthermore, cell based therapies may represent potential strategies in the future.